SciSparc Receives Approval To Conduct Phase IIb Clinical Trial For SCI-110 to Treat Tourette Syndrome In Germany
Portfolio Pulse from Happy Mohamed
SciSparc Ltd. (NASDAQ:SPRC) has received approval from the Federal Institute for Drugs and Medical Devices in Germany to conduct a Phase IIb clinical trial for its drug candidate SCI-110, aimed at treating adults with Tourette Syndrome. The trial will be conducted at three global centers, including the Yale School of Medicine in Connecticut, USA, the Hannover Medical School in Germany, and the Tel Aviv Sourasky Medical Center in Israel. The company has already secured approvals from all three clinical sites and the Israeli Ministry of Health.
June 30, 2023 | 1:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SciSparc's approval to conduct a Phase IIb clinical trial for SCI-110 in Germany could potentially boost its stock as it marks progress in the company's pipeline. However, the final impact will depend on the trial's results.
The approval for the Phase IIb clinical trial is a positive development for SciSparc, indicating progress in its pipeline. This could potentially attract investors, leading to a rise in the stock price. However, the final impact on the stock will depend on the results of the trial, which are yet to be determined.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100